Wire · opportunities
Clinical trials: New mRNA cancer vaccine plus Keytruda sharply improves melanoma survival
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 September 2026 · Fusion42 review
Moderna and Merck's phase 3 clinical trial combining their mRNA cancer vaccine intismeran with Merck's immunotherapy Keytruda showed a significant improvement in melanoma patient survival, with a 49% lower chance of recurrence or death compared to Keytruda alone, potentially leading to FDA approval within months.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 19 Aug 2026 and 14 Sep 2026.
◆ ◆ The Wire takeaway
You need to prepare for rapid adoption of mRNA cancer vaccines like intismeran in melanoma treatment as this combo sharply improves survival and will widen immunotherapy options this year. This creates immediate opportunity to explore partnerships or expand pipelines in oncology focused on personalised immunotherapies.
◆ Coverage
9 sources · first reported 19 Aug 2026 · latest 14 Sep 2026
◆ Topics